靶向CD123的免疫治疗策略在急性髓系白血病中的应用
本文综述了靶向CD123的免疫治疗在复发或难治性急性髓系白血病(AML)中的临床结局,涵盖单克隆抗体、抗体药物偶联物、双特异性T细胞衔接分子及嵌合抗原受体T细胞等策略,并探讨了疗效有限与毒性的潜在原因,最后介绍了临床前开发中的新型CD123靶向方法。
要点
- CD123是AML原始细胞上长期已知的潜在靶点,多种靶向策略已进入试验。
- 靶向CD123的免疫治疗观察到抗肿瘤反应不一且存在毒性。
- 临床前新策略包括靶向CD123与CD33或CLL-1的联合治疗、NK细胞疗法及双特异性分泌T细胞。
核心结论
- 靶向CD123的免疫治疗在复发或难治性AML中显示出可变的抗肿瘤反应和毒性,需关注抗原表达差异、AML微环境及患者来源T细胞适应性等问题。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 靶向CD123的单克隆抗体、抗体药物偶联物、双特异性T细胞衔接分子及嵌合抗原受体T细胞等疗法已进行试验,观察到抗肿瘤反应和毒性不一。
- 治疗相关毒性和疗效有限的潜在原因包括抗原表达差异、AML微环境和患者来源T细胞适应性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin-3 (IL-3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with variable anti-tumour responses and toxicities observed. Here, we review the clinical outcomes of these therapies, including monoclonal antibodies and antibody-drug conjugates, as well as bispecific T-cell engager molecules and chimeric antigen receptor (CAR) T cells. We discuss the potential reasons for therapy-associated toxicity and limited efficacy, including differential antigen expression, the AML microenvironment and patient-derived T-cell fitness. To address these challenges, we highlight novel approaches to CD123 targeting currently in preclinical development. Promising new strategies include combination therapies that target CD123 and other known AML-associated antigens such as CD33 or CLL-1, NK-cell-based cell therapies, and bispecific-secreting T cells.
引用
- Dreyzin A, Holtzman NG, Bonifant CL, et al. CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia. Br J Haematol. 2025. PMID: 40707180. doi:10.1111/bjh.70019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。